Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. - Wikidata - wikimedia - TriplyDB

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

http://www.wikidata.org/entity/Q51528833

about

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases Epigenetic contributions in the development of rheumatoid arthritis Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.The Effect of Stopping Smoking on Disease Activity in Rheumatoid Arthritis (RA). Data from BARFOT, a Multicenter Study of Early RA Alcohol consumption is associated with lower self-reported disease activity and better health-related quality of life in female rheumatoid arthritis patients in Sweden: data from BARFOT, a multicenter study on early RA [Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA].Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression.Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.TNFR2 Deficiency Acts in Concert with Gut Microbiota To Precipitate Spontaneous Sex-Biased Central Nervous System Demyelinating Autoimmune Disease.Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach.Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis.Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients.Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial.Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort.High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate.Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity.Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis.What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review.Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study.Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?Smoking and obesity in systemic lupus erythematosus: a cross-sectional study.Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis.Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis.Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial.Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis.Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.

P2860

Q24185797-43C6F970-F68A-454E-BDDB-94FCFBF592F5 Q26778600-48096926-68C1-4F00-A5B5-84397C4494BD Q26849371-F0E6868B-4F23-4A8E-B4D4-71D24CAE1879 Q30235123-263E09E2-8C42-4701-958A-F674C7CA227D Q30575606-79EE5C96-8ED1-4961-91B0-348200C16958 Q30656861-F2BA5B02-59C6-4628-B121-7BAB5FAC826B Q31032743-9C7FB14A-EDA2-4626-9241-35B15CE63789 Q33747444-F27489BB-5414-4E36-ADED-48F17F4E2DC2 Q34559803-6706B3A1-A3FF-42C5-8047-A3223E859736 Q35012150-FE5AE7FD-3128-4C77-A8D5-0D50B6FA3778 Q35792901-EE089C48-BCB1-473D-A661-1D3F73482E53 Q35811308-3A77CE96-EDC5-4B89-82AB-FC1BCCC6E367 Q35891851-6F556D93-561A-41BA-8249-E44341DCB4FE Q35961312-CBB28B6A-DD4D-4630-A826-B02891A3294E Q36104458-E466A2BD-0A82-4ACC-A21C-AA4BCAB4EA27 Q36306270-A9131292-A69F-4445-8335-50E8D9C02C6C Q36674075-066388BC-75D5-431E-87B6-28F9E9A69AA5 Q36706945-FA5A3AD1-FA27-40BA-AE57-191C0C43E2DF Q36907694-0EB95010-BF4F-4303-8EF2-749E84F7DFD5 Q36960366-39226B59-6052-45DC-B3B3-43C18F69BFC4 Q36983069-CF2C83A8-75E0-43ED-B1FF-F5709337771C Q37065251-19ACDBBA-C07E-4152-BDBB-82CCAAF4BA52 Q37116737-81B1ECCE-800F-4D5C-9208-6D5891780DE7 Q37358983-0412F810-DDF3-4FA3-9654-A874AD793ED0 Q37456609-538A131E-0026-4E73-A4CC-F59227F43B00 Q37689761-6997DE65-33DA-41E0-A51D-182C6B830DA0 Q38024758-AE5763FC-234C-4ABA-87FB-E52BFEC10D64 Q38097740-F25819D7-0FF3-4E89-8992-57EB64DEE8C6 Q38241734-16C0B6A6-BA45-495C-A53E-28042CDCDE94 Q38267703-E96217B8-3298-417E-BC48-0CEFC523955D Q38851071-AAAFDDDA-79EB-44AD-A539-A1F8F321B416 Q38958301-1C0343AD-7276-499B-A51F-95E7A0FDEED0 Q39088676-8F793B74-BC6D-4A11-814D-E599FC04E4F7 Q39154858-3C7F0C3C-7FC8-4175-A9DE-EA3396A193AF Q40403655-499D183D-5747-4C93-B342-2EADA59D3F01 Q40884573-3E46E7AF-5DEB-4C30-A0B2-A835A97D9B95 Q41544053-8888E880-0C37-4ECF-861E-B9CBCACF3029 Q41927602-9A4C728F-A27D-4544-8CD7-752F05878073 Q41931049-11F425DE-396B-43F7-9250-D3EF3129700A Q42674160-E4C43834-2201-45CE-843B-5563002A4610

P2860

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

http://www.wikidata.org/entity/Q51528833

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Predictors of response to meth ...... bel phase of the SWEFOT trial.

@en

Predictors of response to meth ...... bel phase of the SWEFOT trial.

@nl

type

label

Predictors of response to meth ...... bel phase of the SWEFOT trial.

@en

Predictors of response to meth ...... bel phase of the SWEFOT trial.

@nl

prefLabel

Predictors of response to meth ...... bel phase of the SWEFOT trial.

@en

Predictors of response to meth ...... bel phase of the SWEFOT trial.

@nl

P1433

Q51528833-5FFAA71D-525A-43D5-84B6-40FC754BE4E8

P1476

Q51528833-7C841FDE-3150-4773-9307-E129CCE601B5

P2093

Q51528833-0CAD4B60-0323-4C88-9EEB-F296C4EB71D5

Q51528833-3C62F14B-B47E-405E-8121-8EAC05F4359F

Q51528833-65215CE5-780E-4184-8960-5B0236502F43

Q51528833-7D561B2A-A55B-442D-888A-F3E470531E2F

Q51528833-82082A10-A0B7-4022-8C2F-41ACE8D4EE87

Q51528833-82A447F9-AEBB-4735-BB7B-B6BAC849B255

Q51528833-A3783425-89A1-4B0A-9EDE-28FB079003EF

Q51528833-D2BCEEDC-6D29-419D-A579-C6A72E999CDB

P304

Q51528833-54ED60B1-BE5B-45E1-AE03-9702D3B4A895

P31

Q51528833-196C4BC6-4B46-4F54-8643-AD832253C529

P356

Q51528833-D3F16C3F-54F4-4134-9654-1FEA80523995

P407

Q51528833-F760C76B-B7FA-4349-9EF2-5DC6D4F6BCF7

P433

Q51528833-37D8F558-4BCD-4EA0-AD81-06D483E1B160

P478

Q51528833-B6C17C7D-B4A6-4B6B-B2D7-78094C3BF4B3

P50

Q51528833-454A1B5A-60CC-4929-927E-45DFE4F556B4

P577

Q51528833-A956B773-9958-4E7E-AD80-A692D8775647

P698

Q51528833-4178891F-9AC6-4C56-A683-99CCCEE980A2

P356

ARD.2010.139212

P1433

Annals of the Rheumatic Diseases

P1476

Predictors of response to meth ...... bel phase of the SWEFOT trial.

@en

P2093

Helena Wallin

http://www.w3.org/2001/XMLSchema#string

Johan Bratt

http://www.w3.org/2001/XMLSchema#string

Maria Seddighzadeh

http://www.w3.org/2001/XMLSchema#string

Pierre Geborek

http://www.w3.org/2001/XMLSchema#string

Ronald F van Vollenhoven

http://www.w3.org/2001/XMLSchema#string

SWEFOT Trial Investigators Group

http://www.w3.org/2001/XMLSchema#string

Saedis Saevarsdottir

http://www.w3.org/2001/XMLSchema#string

Sofia Ernestam

http://www.w3.org/2001/XMLSchema#string

P304

469-475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2010.139212

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Ingemar F. Petersson

P577

2010-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21149498

http://www.w3.org/2001/XMLSchema#string